Search Results

Join Tria Health and become a healthcare hero. See how you can make a positive impact, today! Become a Healthcare Hero See Open Positions Tria Health Benefits Health, Dental, Life and Disability Insurance HSA Plan with Company Seed $2 a month for employee only health & dental coverage! Plus free life insurance, short and long-term disability insurance and an employee assistance program. Info 401(k) and ROTH Contribution Opportunities 401k with 4% matching. Info Starts accruing immediately! Info Generous Paid Time Off Employee Referral Bonus Tuition Assistance Click Here to View Tria Health's Diversity, Equity, and Inclusion Policy Our Mission We're dedicated to building a partnership of trust with patients and their health care providers to deliver patient-centered and pharmacist-led chronic condition management that results in optimal health outcomes. We're a Friendly Bunch! Tria Health thrives on teamwork and collaboration. We pride ourselves not only on our dedication to our patients, but our work/life balance. By joining Tria Health, you’ll be able to make a direct impact on helping others improve their overall health. Our Community Impact Tria Health believes in giving back! We like to focus our efforts on those charitable activities that support our community the way we support our patients...improving health and education. Tria Health supports: The Folds of Honor ProAm Overrun 5k Adopt a Family And more! PGY1 Community-Based Pharmacy Residency Tria Health offers longitudinal rotations in: Chronic Condition Management (CCM) Resident averages 881 completed appointments per year Evidence-Based Medicine Patient-Centered Dispensing (in collaboration with Albers Medical Pharmacy) Pharmacy Practice Management Research Teaching and Precepting Learn More Open Positions Open Positions Director of Member Experience Full-Time, Exempt View Job Member Engagement Specialist (CSR) PT Part-Time, Non-Exempt View Job Not Finding What You're Looking For? Share your information and we will contact you if new opportunities fitting your qualifications become available. Share Your Information

A growing library of white papers, case studies, webinars, and more. Tria Health Knowledge Center A growing library of white papers, case studies, webinars, and more. Filter by Type All CLINICAL INSIGHTS Making Sense of the WHO's New Obesity Treatment Guidance Read More CLINICAL INSIGHTS Wegovy Pills vs. Injections: What's the Real Difference? Read More WEBINAR GLP-1 Therapies: Trends, Challenges, and Future Outlook Read More CLINICAL INSIGHTS The Role of Pharmacists in Reducing GLP-1 Discontinuation Rates Read More CLINICAL INSIGHTS Unveiling the Future: AI’s Impact on Healthcare Read More PODCAST Pharmacogenomics and Personalized Pharmacy Study Read More WEBINAR Navigating the GLP-1 Wave: Strategies for 2024 Read More ARTICLE Access with Accountability: Managing AOMs Read More WEBINAR Debunking Diabetes Myths: Separating Fact from Fiction Read More CLINICAL INSIGHTS Weight Loss Medications - What's Coming Next Read More CLINICAL INSIGHTS What's New - Standards of Care in Diabetes - 2023 Read More CASE STUDY Improving Patient Outcomes with Pharmacogenomics Read More WEBINAR Diabetes Drugs and Weight Loss - What's the Skinny Read More CLINICAL INSIGHTS New Diabetes Drug Mounjaro Is Likely to Have a Big Impact Read More CLINICAL INSIGHTS Diabetes Drugs and Weight Loss - What's the Skinny Read More PODCAST Industry Voices: Validation Institute Podcast Read More CASE STUDY Tria Health - Validation Institute Study Read More WEBINAR Your Healthcare Game-Changer: Pharmacogenomics Read More WEBINAR How to Successfully Integrate Remote Patient Monitoring Read More CLINICAL INSIGHTS Utilization and Cost of Expensive Diabetes Medications Read More

Tria Health provides one all-encompassing solution to prevent and manage chronic conditions. We improve health and reduce costs, guaranteed. Take Charge of Your Health Talk to a pharmacist over the phone and start your path to a healthier you. Get Started How Does It Work? Pharmacists Know Medications Best Chronic conditions are managed with medications and pharmacists are medication experts. We start with a conversation to understand why your clinical goals are not being met. This info (along with the magic of data and technology) helps us create a care plan for you and your doctor to get you back on track! We start with the medication experts to set you on a path to better health Most people have more than one chronic condition. Focusing only on a specific condition doesn’t give a complete picture of health. Tria Health integrates data from multiple sources, including remote monitoring devices, to turn relevant data into actionable insights. We coordinate care between the member, their physician, caregivers and other benefit solutions to maximize care. It’s risk-free with a 100% financial guarantee. We Provide Financial Savings & Health Outcomes Tria Health provides one all-encompassing solution to prevent and manage chronic conditions. We improve health and reduce costs, guaranteed. Learn More 100% Financial Guarantee $2,579 Average savings per engaged member per year. 1 3.7 : 1 Overall average ROI with 1.7:1 achieved solely from Rx Savings. 1 1.5 Medication related problems identified upon initial consultation. 1 I cannot thank you enough for this service. Tria Health is like a second set of eyes on my health. Appreciate the service. - Rhonda T. View More Tria Triumphs Citations 1. 2024 Tria Health Book of Business Statistics Home Citations

fcd414ca-7040-4667-a9b8-9da2a2bec6ef < Back Clinical Insights Making Sense of the WHO's New Obesity Treatment Guidance Download Clinical Insight A Turning Point in Obesity Care Obesity continues to be one of the most significant and expensive health challenges today.¹ With more than 1 billion people living with obesity worldwide, and rising use of GLP-1 medications, employers are being forced to rethink how they support their populations. The World Health Organization’s new guideline on GLP-1 therapy signals a major shift in how obesity should be treated.¹ It also reinforces something Tria Health has known for a long time: medications alone are not enough. Employees need long-term, whole-person support to see meaningful and sustainable change. WHO GLP-1 Guidelines In December 2025, the WHO released its first global guideline on the appropriate long‑term use of GLP‑1 medications for treating obesity.¹ The organization emphasizes that obesity, like other chronic conditions, requires continuous management rather than quick-fix approaches.¹,² The WHO was clear that medication by itself is not enough to treat a condition as complex as obesity. These medications should also be paired with structured lifestyle support, including nutrition, physical activity, and behavioral counseling.¹,³ While there are still challenges related to cost, access, and long-term data, the recommendations mark a turning point. For the first time, there is global recognition that obesity care must be comprehensive, continuous, and personalized, and that individuals can improve their health through a combination of medical treatment and long-term lifestyle support.¹ What These Changes Mean for Employers GLP‑1 awareness and use has surged in recent years, with employees seeking access for weight loss, diabetes, and cardiovascular benefits.⁴ But covering these medications without guardrails can create significant cost pressures. Employers are increasingly working to strike a balance - supporting meaningful access to obesity care while ensuring coverage remains financially sustainable. The WHO guidelines reinforce what many employers are already experiencing: GLP‑1s require careful oversight to manage dosage, safety, and appropriate duration of therapy.¹,³ Long‑term success depends on supporting the whole person, not just approving a prescription.¹ Structured behavioral support should be required, not optional. Fragmented or “quick‑win” point solutions fall short. Employers need integrated programs that address behavior, comorbidities, and medication optimization. Forward‑thinking employers are already moving toward models that align with WHO’s recommendations. Many are adopting requirement-based pathways for GLP‑1 coverage, tightening eligibility, and pairing medication access with coaching and lifestyle‑change programs. How Tria Health Meets and Exceeds WHO’s Standard for Comprehensive Care Unlike programs that rely solely on medication, Tria Health supports members with or without GLP-1 therapy - ensuring every individual receives the right care based on their unique needs. Our care team, including both pharmacists and health coaches, helps members improve their health whether or not they use GLP‑1 medications. We support members by: Offering guidance for those prescribed GLP‑1s, which are complex medications that require careful dose adjustment, adherence oversight, and ongoing monitoring to ensure safe and effective use Providing personalized lifestyle, nutrition, and behavior‑change coaching for all participants Supplying a cellular body composition scale so members can easily track progress and share updates with their health coach Helping members build long‑term habits that support sustainable weight and chronic condition management, with or without medication This whole‑person approach gives employers a single, integrated solution that supports long‑term health, improves outcomes, and controls unnecessary costs. What Employers Need to Know Moving Forward Employers must balance access, cost, and long‑term health outcomes. Because these medications are costly, plans need strong support systems in place to prevent unnecessary spending and to ensure they lead to real improvements in employee health.⁵ The most effective strategy is one that pairs appropriate medication use with long‑term lifestyle support, clear expectations, and strong clinical guidance. To navigate this shift, employers should: Review and refine GLP‑1 coverage criteria to ensure alignment with clinical best practices while reflecting on the organization’s philosophy around responsible, sustainable care Require participation in lifestyle or behavior‑change programs for members using GLP‑1s Incorporate clinical guidance to reduce unnecessary pharmacy spend and improve safe use Equip members with tools and coaching that support sustainable progress beyond medication Prioritize whole‑person chronic condition support instead of fragmented point solutions By taking these steps, employers can protect their benefit budget, support long‑term health outcomes, and create a more sustainable strategy as obesity treatment continues to evolve. Conclusion: A Smarter Path Forward for Obesity Care The WHO’s new GLP‑1 guideline confirms that obesity is a chronic condition requiring comprehensive support. ¹,² Medication alone cannot address the full scope of the problem, and employers who rely on prescription‑only solutions risk higher costs with limited outcomes. ¹,³ References 1. WHO Issues Global Guideline on the Use of GLP‑1 Medicines in Treating Obesity http://WHO Issues Global Guideline on the Use of GLP‑1 Medicines in Treating Obesity 2. PAHO/WHO: Guideline on the Use of GLP‑1 Therapies for Obesity in Adults https://www.paho.org/en/documents/who-guideline-use-glucagon-peptide-1-glp-1-therapies-treatment-obesity-adults 3. HealthDay / U.S. News: WHO Issues First Guidance on Using GLP‑1 Drugs to Treat Obesity https://www.usnews.com/news/health-news/articles/2025-12-02/who-issues-first-guidance-on-using-glp-1-drugs-to-treat-obesity 4. JAMA: What to Know About the WHO’s New GLP‑1 Drug Guideline https://jamanetwork.com/journals/jama/fullarticle/2843811 5. PHTI Market Trend Report: Employer Approaches to GLP‑1 Coverage https://phti.org/employer-approaches-to-glp1-coverage/ Previous Next

d7e78db7-ebb6-480e-93a9-6aa24508ed7b < Back Clinical Insights Utilization and Cost of Expensive Diabetes Medications Keeps Increasing – What is Behind this Change? Download Clinical Insight As recently as 2018, established guidelines for management of diabetes (American Diabetes Association, ADA, and American Association of Clinical Endocrinology, AACE) had no specific preference of therapy choice outside of metformin for A1c lowering. However, in the last few years, several studies have been conducted that have driven guideline changes for preferential initial or adjunctive therapies in diabetes. National treatment guidelines are typically slow to evolve as new agents must have strong supporting evidence not only for HbA1C lowering but also improved overall health outcomes or reduction in risk for comorbid conditions. Since 2018 there has been multiple published studies supporting the benefits of two classes of diabetes medications, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (eg Farxiga and Jardiance) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (eg Ozempic and Trulicity). Both classes of medications represent new and novel mechanisms of action that have proven to produce potent blood sugar and HbA1C lowering. Why are these medications recommended over less expensive medications? While prior classes of antidiabetic medications will always have a place in therapy for additional A1c lowering, they do not (outside metformin) carry benefits to improve or reduce risk of comorbid conditions or complications that diabetes can cause. An overview of these conditions include: Obesity: Obesity-related costs were nearly $173 billion to the US health system in 2019 Weight loss can help slow the progression from prediabetes to type 2 diabetes Weight loss is also beneficial in treatment of type 2 diabetes in helping lower blood sugar and reducing medication needs Cardiovascular Disease: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of complications and death in diabetes ASCVD includes coronary heart disease, cerebrovascular disease, and peripheral arterial disease—or the buildup of blockage in blood vessels that can lead to heart attack, stroke, and lowered circulation to the hands and feet Diabetes alone is a risk factor for developing ASCVD, as are common comorbid conditions of high blood pressure and high cholesterol An estimated $37.3 billion is spent on cardiovascular-related concerns associated with diabetes Heart Failure: Heart failure is a major cause of complications and death from cardiovascular disease Rates of hospitalization from heart failure complications are doubled in patients with diabetes than patients without Chronic Kidney Disease: Occurs in 20-40% of patients with diabetes In patients with diabetes, CKD increases the ASCVD risk and causes increase in healthcare costs Progression of CKD can lead to need for dialysis or kidney transplant The SGLT2 Inhibitors and GLP-1 Agonists have become preferred medications as they have shown the ability to reduce the occurrence or progression of these conditions and improve outcomes for patients with diabetes. GLP-1 Agonists: This class of medications includes injectables Adlyxin, Byetta, Ozempic, Trulicity, and Victoza and oral Rybelsus, and work through a few ways to lower blood sugar, one of which includes weight loss. Weight loss is seen as an added benefit for many patients with type 2 diabetes. Studies have also shown a reduced risk of cardiovascular events with Ozempic, Trulicity, and Victoza. The ADA recommends GLP-1 therapy as an initial therapy option in patients with diabetes who already have or are at high risk for heart disease. SGLT2 Inhibitors: SGLT2 Inhibitors include Farxiga, Invokana, Jardiance, and Steglatro. In addition to their blood sugar and HbA1C lowering benefits, SGLT2 Inhibitors have also been approved by the FDA for treatment of chronic kidney disease and heart failure. Studies have also found reduced risks of cardiovascular events and progression of kidney disease in people with diabetes. Because of these benefits, SGLT2 Inhibitors are recommended as an initial therapy option in patients who have or at high risk for chronic kidney disease, heart failure, and cardiovascular disease. Additionally, in patients with kidney disease or heart failure, these medications are often prescribed outside of a diabetes diagnosis due to their benefits of delaying progression of these conditions. A New Way to Achieve Potent Blood Sugar and HbA1C Lowering Despite the increase in costs for both the health plan and the patient, these medications are recommended for early treatment in patients who are at high risk or already diagnosed with comorbid conditions. Treatment with these medications could help patients avoid certain complications entirely or help slow progression of these conditions to both more costly and more symptomatic stages of disease, in addition to their A1c-lowering benefits. By reducing the risk of diabetes complications, the pharmacy expenditures will likely be offset by a reduction in medical costs for cardiovascular events and kidney disease. References American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45 (Suppl. 1):S8-S264. CDC. Adult Obesity Facts. https://www.cdc.gov/obesity/data/adult.html. Sep 2022. Previous Next

05185c71-9d18-41ba-a37b-d03a2baeb7c9 < Back Clinical Insights Unveiling the Future: AI’s Impact on Healthcare Download Clinical Insight Artificial intelligence (AI) has been around for decades but burst to the forefront of our minds after ChatGPT was released to the public in late 2022. The sudden appearance of such an interactive and convincing use of AI in chatbot form resulted in it being the fastest application to reach one hundred million users in history.1-2 Numerous other large technology players and smaller startups have developed their own AI chatbots and other applications based on these AI platforms. Already, AI impacts nearly all industries in some way, and healthcare is certainly no exception. Overall, AI encompasses programs that perform functions traditionally performed by humans. In a narrower scope, healthcare AI programs operate within many aspects of day-to-day services including 3-6: Imaging evaluation and interpretation Clinical diagnostics, both subjectively and objectively Providing clinical insights and decision support Documentation efficiency Treatment response prediction Administrative functions, including scheduling and written responses to emails and messages As AI programs evolve and expand, additional AI use cases in healthcare are expected. Some early stage and future expected applications include 6-7: Mining large datasets to identify difficult-to-detect trends and patterns Helping clinicians apply clinical evidence more accurately to patient cases Targeted drug discovery and development Predict treatment response via disease markers Integrate personalized medicine factors like genomics into treatment decisions Help overcome barriers to healthcare management including social determinants of health, cost, and access challenges Better prepare for a population’s healthcare utilization needs Reduce administrative burdens like writing chart notes, summarizing medical information, purchasing and inventory management, billing, and completing routine administrative tasks As we move into this new age of AI integration within healthcare and all aspects of business and life, questions remain. What are the ethical implications? Who vets AI-generated information, confirms validity and accuracy, and holds these programs accountable? What role do humans and professionals play in this new era? We’ll explore these topics more throughout this series as we venture into an exciting and nerve-wracking ecosystem of technology applications in arguably the most human of businesses: healthcare. References Roser M. The brief history of artificial intelligence: The world has changed fast – what might be next? Our World in Data. Published December 6, 2022. https://ourworldindata.org/brief-history-of-ai Wodecki B. UBS: ChatGPT is the Fastest Growing App of All Time. AI Business. Published February 3, 2023. https://aibusiness.com/nlp/ubs-chatgpt-is-the-fastest-growing-app-of-all-time IBM Education. The benefits of AI in healthcare. IBM Blog. Published July 11, 2023. https://www.ibm.com/blog/the-benefits-of-ai-in-healthcare/ Roy A. Artificial intelligence: 10 promising interventions for healthcare. NIHR Evidence. Published July 28, 2023. https://evidence.nihr.ac.uk/collection/artificial-intelligence-10-promising-interventions-for-healthcare/ Berry MD. Understanding the advantages and risks of AI usage in healthcare. Thomson Reuters Institute. Published September 27, 2023. https://www.thomsonreuters.com/en-us/posts/technology/ai-usage-healthcare/ Alowais, S.A., Alghamdi, S.S., Alsuhebany, N. et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ 23, 689 (2023). https://doi.org/10.1186/s12909-023-04698-z Bhasker S, Bruce D, Lamb J, Stein G. Tackling healthcare’s biggest burdens with generative AI | McKinsey. www.mckinsey.com . Published July 10, 2023. https://www.mckinsey.com/industries/healthcare/our-insights/tackling-healthcares-biggest-burdens-with-generative-ai Previous Next

5f13fecd-587f-46ae-a3b0-71c1a711b447 < Back Clinical Insights Weight Loss Medications: What’s Coming Next? Download Clinical Insight Medications like Ozempic, Wegovy, and Mounjaro have taken the world by storm because of their effects on weight loss and opened eyes to the new possibilities that weight loss medications can bring. Before these new medications arose, weight loss research seemed to stall, with prior therapies seeing approximately a 6-19 pound weight loss over the course of a year when added to diet and exercise.1 However, with the development of new glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (branded as Wegovy for weight loss; Ozempic for diabetes) averaging a 22-27 pound weight loss in a year and beyond1, drug companies have a rejuvenated interest for developing weight loss medications, with several new candidates likely coming on the market in the coming years. Taking their lead from the success of the GLP-1 receptor agonist family, several new medications under investigation continue to utilize this mechanism and build upon it by affecting other gastric hormones (incretin hormones) that may further enhance weight loss. One such example that will likely be the next approved weight loss medication is tirzepatide (currently available as brand name Mounjaro for diabetes), which combines the effect of GLP-1 receptor agonists along with activating another incretin hormone pathway, glucose-dependent insulinotropic polypeptide (GIP), allowing for enhanced weight loss benefits up to 15% body weight loss (34.4 pounds) in a year and a half. 2 Additional incretin-active drugs under investigation that we may see in the coming years include ecnoglutide, mazdutide, retatrutide, orfoglipron, and CagriSema, which not only provide additional weight loss options, but also oral tablet forms rather than injectable only, as the current options are. Many New Drugs are Building on the Success Mechanisms of GLP-1s A novel medication early in studies is ARD-101, which continues with the incretin hormone trend but also adds a unique mechanism of targeting extraoral bitter taste receptors (TAS2R). This product seems to not only provide benefits in both weight loss and appetite suppression, but also inflammation. The researchers are beginning studies to look at ARD-101 for both metabolic and inflammatory conditions.3 Rather than supplement incretin hormones, APH-012 is under investigation as a more “natural” option to help re-regulate the body’s own incretin hormone response. It consists of a glucose (sugar) formulation taken before meals that is designed to break down at specific and strategic parts of a person’s digestion to help re-regulate and optimize when each incretin hormone response occurs after eating.4 One concern that has arisen from incretin hormone weight loss medications like Wegovy is that weight loss is not coming from fatty tissue only, but also from loss of muscle mass. While the long-term impact of this is unknown, it does raise concerns as muscle is important for enhancing weight loss through burning through fatty tissue, as well as general need for mobility and safety of preventing falls and bone fractures. Bimagrumab is a novel medication under investigation that is a monoclonal antibody (essentially a synthetic protein that matches a biological protein) that has been found to increase muscle growth while simultaneously lowering body fat.5 Bimagrumab is being tested both by itself as well as with semaglutide (Wegovy) to determine best weight loss results while maintaining muscle mass. Another drug taking a unique approach is RES-010, which is instead focusing its mechanism on RNA (i.e., “recipes” that cells use to make different proteins throughout the body). The investigators have identified a target of miR-22 that is involved with regulation of metabolism, and found that with controlling miR-22, they may be able to control multiple factors around metabolism.6 These are only a handful of several of the new weight loss medications that we may see come to market over the next few years. With so many new agents becoming available, the questions of why it matters and what to do with all these options remain—however, having options is ideal for patients so that treatment can be tailored and targeted for each individual’s needs. These options now allow adjustments for safety, considerations for concomitant health conditions, management of side effects and tolerability, as well as preference for administration. Impacts to Obesity Management With 42% of Americans considered obese (BMI greater than 30), these medications will continue to play a larger role in obesity management. However, it is crucial to recognize that medication alone cannot provide a complete solution. The integration of nutrition and physical activity counseling is imperative for optimal health outcomes. Many people suffering from obesity require education to adopt healthier behaviors. This lifestyle counseling will ensure that once a healthy weight is achieved, it can be maintained without having to take medication for life. References Clinical Resource, Weight Loss Products. Pharmacist’s Letter/Prescriber’s Letter. August 2021. [370802] Lilly. Lilly’s Tirzepatide Achieved up to 15.7% Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2. Investor.lily.com. Published April 27, 2023. Accessed May 12, 2023. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or Aardvark Therapeutics, Inc. Aardvark Therapeutics, Inc., Announces the Initiation of Enrollment for Three Phase 2 Clinical Trials of Oral ARD-101. Prnewswire.com. Published February 2, 2022. Accessed May 12, 2023. https://www.prnewswire.com/news-releases/aardvark-therapeutics-inc-announces-the-initiation-of-enrollment-for-three-phase-2-clinical-trials-of-oral-ard-101-301473522.html. Aphaia Pharma. First Patient in Phase 2 Study of APH-012. Aphaiapharma.org. Published October 27, 2022. Accessed May 12, 2023. https://aphaiapharma.com/news/first-patient-in-phase-2-study/. Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021;4(1):e2033457. doi:10.1001/jamanetworkopen.2020.33457 Vitale, Gina. Resalis Takes Aim at ‘Master Regulator of Metabolism’. Cen.acs.org. Published February 22, 2023. Accessed May 30, 2023. https://cen.acs.org/biological-chemistry/rna/Resalis-takes-aim-master-regulator/101/web/2023/02. Previous Next

43b695a0-c46f-4de2-839a-295c3fdf1758 < Back Clinical Insights Wegovy Pills vs Injections: What's the Real Difference? Download Clinical Insight As GLP-1 medications like Wegovy continue to reshape weight-loss treatment, people now have more options than ever, including the newly approved oral (pill) form. Both the pill and injection versions can be effective tools for weight management, but they have important differences and unique considerations that should be discussed before starting treatment. Understanding these differences is essential, especially when deciding which medication to take. Pairing these medications with meaningful lifestyle and behavior change is still critical for long-term success. When combined with expert guidance from a pharmacist, employees receive the support they need to use the medication safely, manage side effects, build healthier habits, and maintain progress over time. How Wegovy Pills and Injections Work Both forms use the same type of active ingredients, which helps regulate appetite, slow digestion, and support weight loss. The differences come down to how the medication enters the body.¹ Wegovy Injections Delivered under the skin, usually once weekly. Provide more predictable absorption because the medication is not digested through the GI tract.¹ Require comfort with needles but offer simple weekly dosing. Wegovy Pills Taken by mouth once daily. Require strict timing and administration, such as taking on an empty stomach with a small sip of water and waiting before eating, drinking, or taking other medications.¹ Less than 1 percent of the medication is absorbed due to digestion, so dosages are higher and adherence is very important.² Which Option Is More Effective? Both Wegovy Pills and injections have been shown to support meaningful weight loss, but how effective they are can depend on several factors, including how your body absorbs the medication, your daily routine, and how consistently you take it. Injectables generally offer more predictable absorption, since they bypass the digestive system. Many patients experience around 15 percent or more total body‑weight reduction with injectable semaglutide options like Wegovy.³ Oral Wegovy can achieve similar outcomes, with clinical trials showing 16 to 17 percent weight loss for those who take the pill consistently and follow strict timing instructions.⁴ Absorption varies more with pills, which can make their effectiveness more dependent on daily routine and proper use, while injections provide steadier, more predictable results. It’s also important to note that the weight‑loss results seen in clinical trials for both the oral and injectable forms were not achieved by medication alone, but by combining GLP‑1 therapy with reduced‑calorie diets and increased physical activity.³,⁴ Side Effects and Safety Considerations Both forms share similar side effects because they contain the same active ingredients. These may include nausea, reflux, vomiting or diarrhea, and/or constipation. However, the pill does come with extra timing‑related safety considerations.¹ To make sure your body absorbs the medication correctly, you must: Take it first thing in the morning on an empty stomach. Swallow it with no more than 4 oz (about ½ cup) of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other medications. Avoid splitting, crushing, or chewing the pill. Why Pharmacist Support Is Essential for Long‑Term Success Whether choosing pills or injections, GLP‑1 therapy can be complex. Pharmacist involvement plays a crucial role in helping individuals get the best possible results. Pharmacists help patients: Manage proper timing, dosing, and titration. Many people stay on the starter dose or try to stop the medication once they see initial results, but following the full titration schedule is essential for safety and long‑term effectiveness. Monitor and manage side effects early, preventing discontinuation. Identify drug interactions, particularly because GLP‑1s delay digestion and can affect how other medications are absorbed. Stay on track with treatment, improving adherence and reducing wasted costs. This level of support helps prevent common pitfalls such as staying on the starter dose, stopping the medication prematurely, or using it in ways that limit effectiveness. Without this guidance, employees may never reach therapeutic doses or stick with treatment long enough to benefit, leading to significant wasted spend for employers investing in these high‑cost medications. Takeaway for Employers & Patients Both Wegovy Pills and injections are effective tools for weight loss, but the right choice depends on personal preferences, daily habits, and medical needs. These medications also work best when paired with meaningful lifestyle and behavior changes, which remain essential for long‑term results. Because GLP‑1 therapies require careful titration, ongoing monitoring, and consistent lifestyle support, having a pharmacist and coaching team involved can make a measurable difference in safety, adherence, and overall outcomes. If your organization is evaluating GLP‑1 coverage or supporting employees using these medications, partnering with a pharmacist‑led service like Tria Health can help ensure employees take the medication correctly, develop sustainable habits, and stay engaged long enough to benefit. References 1. GoodRx: Wegovy Pill vs Injection – Key Differences https://www.goodrx.com/wegovy/pills-vs-injection 2. PMC: Semaglutide and Cardiometabolic Effects in Obesity https://pmc.ncbi.nlm.nih.gov/articles/PMC8505367/ 3. NEJM: Once‑Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial) https://www.nejm.org/doi/10.1056/NEJMoa2032183 4. NEJM: Oral Semaglutide for Obesity – OASIS‑4 Trial Results https://www.nejm.org/doi/full/10.1056/NEJMoa2500969 Previous Next

ca427bcf-b4c1-4153-b1c1-c52424510aee < Back Clinical Insights The Essential Role of Pharmacists in Reducing GLP-1 Discontinuation Rates Download Clinical Insight GLP-1 receptor agonists have become a cornerstone in managing type 2 diabetes and obesity, offering significant benefits in glycemic control and weight loss. However, a recent study published in JAMA reveals a concerning trend: 53.6% of adults prescribed a GLP-1 receptor agonist discontinued therapy within one year, and 72.2% stopped within two years.¹ This high discontinuation rate highlights the need for effective strategies to support patients selecting the appropriate medication and providing continuous monitoring to prevent early discontinuation. Pharmacists, with their specialized knowledge and patient-centered approach, are uniquely positioned to reduce these discontinuation rates. GLP-1s: A Game-Changer for Diabetes Management GLP-1 receptor agonists work by mimicking the action of the glucagon-like peptide-1 hormone, which helps regulate blood sugar levels and appetite. These medications have been shown to improve glycemic control, promote weight loss, and reduce the risk of cardiovascular events in patients with type 2 diabetes. While much of the focus has been on the use of GLP-1s for obesity and the associated healthcare costs, it's important to remember that these medications are also widely accessible and popular among patients with diabetes. In fact, about 1 in 5 US adults with type 2 diabetes were using GLP-1 receptor agonists by 2022.² Despite their benefits, patients with diabetes face the same challenges with GLP-1s, including side effects such as nausea and vomiting, high medication costs, and issues related to adherence, leading to similar discontinuation rates. Unpacking the Study: What the Numbers Reveal The study published in JAMA aimed to investigate the discontinuation rates of GLP-1 receptor agonists among adults. Researchers analyzed a large sample of patients over a two-year period, tracking their adherence to the prescribed therapy. The findings were striking: more than half of the patients discontinued their therapy within the first year, and nearly three-quarters did so by the end of the second year. Factors contributing to these high discontinuation rates included side effects, availability, cost, and lack of patient education and support.¹ Sample Size and Demographics : The study included a diverse group of over 125 474 adults from various backgrounds. Side Effects Leading to Discontinuation : Approximately 20% of patients reported side effects severe enough to consider stopping the medication. Cost Leads to Discontinuation : Lower income was associated with higher discontinuation rates. Adverse effects and costs were the most frequently mentioned reasons for discontinuation. The Financial Impact on Employers The rising use of GLP-1 receptor agonists, such as Ozempic and Wegovy, is significantly impacting employer healthcare budgets. These medications, while effective for managing type 2 diabetes and obesity, come with high costs that can strain employer-sponsored health plans. For instance, the annual cost of GLP-1 medications can exceed $10,000 per employee.³ As more employees seek these treatments, employers face increasing financial pressure to cover these expenses. Some employers are implementing strategies like prior authorization and higher cost-sharing requirements to manage these costs.⁴ Employers face a growing challenge in balancing the benefits of improved employee health with the financial burden of these medications, especially given the high discontinuation rates. Pharmacists: The Unsung Heroes in Patient Support Pharmacists are uniquely equipped to support patients on GLP-1 therapy through comprehensive medication counseling and education. They can help patients understand the benefits and potential side effects of their medication, manage expectations, find patient assistance coupons, identify cost-effective alternatives, and offer practical advice on lifestyle modifications. Pharmacists also play a crucial role in monitoring patients for adverse effects, addressing concerns promptly, and offering solutions to improve adherence. By building strong relationships with patients, pharmacists can help overcome barriers to continued use of GLP-1 receptor agonists, ultimately reducing discontinuation rates. Pharmacists Improve Medication Adherence: Research indicates that pharmacist-led interventions can improve medication adherence by up to 30%.⁴ Pharmacists Can Track and Educate on Drug Reactions: Many pharmacists have specialized training in diabetes management and medication therapy management, making them well-suited to support patients on GLP-1 therapy.⁵ Conclusion The high discontinuation rates of GLP-1 receptor agonists highlighted in the recent study are a significant concern for the management of type 2 diabetes and obesity. Pharmacists, with their specialized knowledge and patient-centered approach, are essential in addressing this issue. By providing education, support, and personalized care, pharmacists can help patients maintain their therapy and achieve better health outcomes. Healthcare systems should recognize and leverage the critical role of pharmacists in managing GLP-1 therapy to ensure patients receive the full benefits of their treatment.⁶ References JAMA Network Open. (2025). High discontinuation rates of GLP-1 agonists found among patients with obesity. JAMA Network Open, 8 (1), e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349 Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes. (2022). Journal of Diabetes Research . https://doi.org/10.2337/dc21-1815 WTW. (2024). GLP-1 Drugs: Implications for Employer Health Plans. Retrieved from https://www.wtwco.com/en-us/insights/2024/02/glp-1-drugs-implications-for-employer-health-plans Healthcare Business Today. (2024). Employers' Dilemma: Weight Loss Drugs Coverage. Retrieved from https://www.healthcarebusinesstoday.com/employers-dilemma-weight-loss-drugs-coverage/#google_vignette Pharmacy Focus: GLP-1 Medications and Pharmacists' Role in Counseling Patients. (2024). Pharmacy Times . Retrieved from https://www.pharmacytimes.com/view/pharmacy-focus-glp-1-medications-and-pharmacists-role-in-counseling-patients Clinicians, Pharmacists Should Work to Ensure Safety Compounded GLP-1 Medications. (2024). American Pharmacists Association . Retrieved from https://www.pharmacytimes.com/view/clinicians-pharmacists-should-work-to-ensure-safety-compounded-glp-1-medications Q&A: Pharmacists Play Pivotal Role in Evolving Diabetes Care with New Treatments. (2024). Diabetes Care Journal . Retrieved from https://www.pharmacytimes.com/view/q-a-pharmacists-play-pivotal-role-in-evolving-diabetes-care-with-new-treatments Previous Next

bb0d492b-07cc-403c-a059-42759ed2baae < Back Clinical Insights New Diabetes Drug Mounjaro Is Likely to Have a Big Impact Download Clinical Insight There is a new player on the field of diabetes management and based on early anecdotal reports and clinical trial data, it may establish its place sooner than later. Tirzepatide (tir ZEP a tide), branded as Mounjaro (mOUn-jar-O, like “mountain”) from Eli Lilly, was approved for type 2 diabetes in May 2022 and uses a novel mechanism of action to help lower A1c. Mounjaro is the first GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-dependent Insulinotropic Polypeptide) agonist available on the market. Mounjaro is a once-weekly injectable medication packaged in prefilled syringes at various doses. It does require a gradual dose titration over weeks to months to reach the maximum target dose (2.5 mg up to 15 mg).1 Mounjaro was approved based upon the results of multiple clinical trials showing its ability to significantly lower HbA1C. In these studies, Mounjaro was compared to either insulin therapy (Tresiba or Lantus) or injectable GLP-1 therapy (Ozempic). In all completed trials, Mounjaro not only showed significant decreases in A1c by over 2%, but also proved superior to all comparators, respectively. Additionally, greater weight loss was seen with Mounjaro, particularly at the maximum dose of 15 mg once a week, than any comparator medication. Mean weight loss of 15-20% of body weight (35-52 pounds) has been seen in studies and Eli Lilly is pursuing an FDA indication for obesity treatment. This degree of weight loss is greater than what has been shown with current obesity treatments Saxenda and Wegovy. Side effects were similar between groups, with gastrointestinal distress being the most common, but this led to few patients overall stopping treatment.2-6 Cardiovascular and renal outcome studies are underway and will be completed by 2024. Although the diabetes management arena is crowded with medications from a variety of classes, the evidence supporting Mounjaro suggests it will stake its claim among the contenders to help try to close the gap in lowering A1c and improving outcomes for people with type 2 diabetes. Pricing will vary based on insurance contracting, but cash prices are estimated in line with other once-weekly GLP-1 agonists of around $1,000 per 4 weeks, or $13,000 per year.11-12 Sales are forecasted up to $4.9 billion by 2026 and up to $14 billion by 2030.13-14 The manufacturer offers a copay assistance program that lowers the out-of-pocket cost to $25 for patients for 1- or 3-month supplies and currently applies with or without commercial insurance.15 While formulary coverage will likely evolve and expand approaching 1/1/2023, at least one searchable plan already accommodates Mounjaro, although with prior authorization to ensure use for FDA-approved indications.16 Mounjaro represents an exciting new direction for type 2 diabetes management and is likely to gain significant traction among prescribers and patients, especially if added to major national formularies in 2023. National treatment guidelines such as the American Diabetes Association Standards of Medical Care will likely give an asterisk on its use until cardiovascular outcome results are available, but that is unlikely to be a major hurdle to use given the dramatic A1c- and weight-lowering effects seen already. Whether or not Mounjaro represents the first of many combined GLP-1/GIP agonists is to be determined, the evidence described above makes this product one to be aware of in the ever-changing diabetes management landscape. References Mounjaro. Package insert. Eli Lilly and Company; 2022. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. doi:10.1016/S0140-6736(21)01443-4 Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. doi:10.1016/S0140-6736(21)02188-7 Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–545. doi:10.1001/jama.2022.0078 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6). ClinicalTrials.gov. Accessed August 26, 2022. https://clinicaltrials.gov/ct2/show/NCT04537923 Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418-429. doi:10.1016/S2213-8587(22)00085-7 Jill Rollet. SUPRASS-4: Tirzepatide slows kidney disease in adults with type 2 diabetes, CV risk. Healio News. June 4, 2022. Accessed August 26, 2022. https://www.healio.com/news/endocrinology/20220603/surpass4-tirzepatide-slows-kidney-disease-in-adults-with-type-2-diabetes-cv-risk Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 Urtė Fultinavičiūtė. Lilly eyes weight loss arena for diabetes drug tirzepatide after positive data. Pharmaceutical Technology. June 10, 2022. Accessed August 26, 2022. https://www.pharmaceutical-technology.com/news/lilly-tirzepatide-weight-loss/ Mounjaro. GoodRx. Accessed August 26, 2022. https://www.goodrx.com/mounjaro?dosage=4-pens-of-12.5mg-0.5ml&form=carton&label_override=Mounjaro&quantity=1&sort_type=popularity Mounjaro Prices, Coupons and Patient Assistance Programs. Drugs.com. Accessed August 26, 2022. https://www.drugs.com/price-guide/mounjaro Kevin Dunleavy. Lilly's highly anticipated diabetes drug Mounjaro wins FDA blessing. Fierce Pharma. May 13, 2022. Accessed August 26, 2022. https://www.fiercepharma.com/asia/lillys-highly-anticipated-diabetes-drug-mounjaro-blessed-fda Jaimy Lee. Mizuho: Lilly's newly approved diabetes drug expected to bring in $14 billion in sales by 2030. MarketWatch. May 16, 2022. Accessed August 26, 2022. Previous Next

f4671ade-31e5-45f7-9aa7-442fb563b08e < Back Clinical Insights What’s New in Diabetes Care – Standards of Care in Diabetes - 2023 Download Clinical Insight Every January, the American Diabetes Association (ADA) updates their Standards of Care in Diabetes to include the most recent medication approvals and cutting-edge evidence for diabetes management. The Standards of Care includes all aspects of diabetes prevention, diagnosis, and management, and is one of the most valuable guidelines for clinicians who work with people with diabetes. Some of the updates included this year included: New recommendations for weight loss and medications that can help facilitate weight loss More conservative biometric goals in persons with diabetes New medication recommendations for management of complications in diabetes Expansion of technology, telehealth, and telemedicine Weight Loss The ADA has taken a stance this year that obesity is a chronic and often progressive health condition and should be treated as such through several modalities to help with weight loss, both in people who have diabetes or who have prediabetes. Behavioral therapy is recommended to help guide patients to more nutrient-dense foods, reduce calorie intake, and effective exercise plans. Clinical benefits can be seen in as little as 3% weight loss, and more intensive weight loss can help achieve further health improvements. With the development of incretin mimetics (such as Ozempic, Trulicity, and Mounjaro) to treat diabetes and the added benefit of helping with weight loss, patients can see much more substantial weight loss that can help achieve blood sugar goals and avoid or prevent the progression of complications; in patients with prediabetes, this weight loss can also help stop and reverse progression towards diabetes. As a result of this, the ADA is recommending as much as a 15% weight loss, which can be achieved through comprehensive weight management treatment with incretin mimetics combined with intensive behavioral therapy. Biometric Goals Diabetes alone is a risk factor for experiencing a heart attack or stroke, and having elevated blood pressure or cholesterol continues to increase this risk. Because of this, the ADA is taking a stronger stance on controlling blood pressure and cholesterol. In regard to high blood pressure, the ADA previously recommended a blood pressure goal of less than 130/80 mmHg but diagnosed hypertension at a blood pressure above 140/90 mmHg. With the 2023 update, they have lowered this diagnosis level to match the treatment goal, as well as align with the American Heart Association and American College of Cardiology diagnosis of hypertension at blood pressures above 130/80 mmHg. This change encourages faster action for initiation of medication to begin lowering blood pressure to help protect the heart and reduce risk of heart attack and stroke. An additional benefit with this approach is the preservation of the blood vessels that provide oxygen to organs and reduce the risk of organ damage, such as kidney damage and vision loss. In persons who have already experienced a heart attack or stroke, the ADA is also taking additional measures to help prevent an additional recurrence through more conservative cholesterol goals. Previously, the ADA recommended LDL (or “bad” cholesterol) to be less than 70 mg/dL; however, in light of newer evidence, they are recommending further LDL lowering to less than 55 mg/dL. To do this, they recommend first-line to utilize a family of medications called statins, as these have the most evidence showing reduction of heart attack and stroke, as an initial or subsequent event. Managing Complications of Diabetes Common complications that exist with diabetes include heart failure and kidney disease, which can be both costly and cause a variety of quality-of-life disruptions for people with these conditions. The ADA has provided guidance regarding new medications available for these conditions to help slow the progression and reduce symptoms. A family of medications called SGLT2 inhibitors (Farxiga, Jardiance) that has previously been approved for diabetes to lower blood sugar is also now recommended in kidney disease to help prolong kidney function, and now is also recommended in people with diabetes and heart failure. Studies have proven benefit with these medications to maintain heart function, reduce the risk of heart-related death, and overall help reduce symptoms associated with heart failure. These medications are being recommended for anyone with any cardiovascular concerns, such as a prior heart attack, or impaired kidney function with diabetes. Along these lines, studies have shown a new medication finerenone (Kerendia) provides benefit in people with diabetes who have kidney disease with albuminuria (protein in the urine) by helping reduce the risk of progression of kidney disease, as well as improves cardiovascular outcomes. The ADA recommends the consideration for use of finerenone to be used in people with diabetes with kidney disease and any risk factors that may make them more at risk for a heart attack or stroke. Formulary and Plan Design Implications Tria Health recommends including incretin mimetics in your formulary. However, since these medications are expensive, Tria Health recommends including a prior authorization that requires a diabetes diagnosis to ensure these medications are not being prescribed and used off-label. In addition, Tria Health recommends including incretin memetics to treat obesity as well, but these should also include a prior authorization that requires an intensive weight management program to ensure necessary lifestyle behavior changes occur. Similarly, making CGMs available to those members who would benefit is appropriate. The key is having a skilled practitioner, like a Tria Health pharmacist, who can consult with the patient to determine the appropriate course of action to ensure that the right medication or device is getting to the right patient at the right time. This will maximize health outcomes while reducing plan waste. References The American Diabetes Association’s Standards of Care in Diabetes – 2023 in full text can be accessed through https://diabetesjournals.org/care/issue/46/Supplement_1. ElSayed NA, Aleppo G, Aroda VR, et al., American Diabetes Association. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes—2023. Diabetes Care 2023;46(Suppl. 1):S128–S139 Previous Next

From success stories to testimonials, Tria Health's patient impact is something we love to share! I cannot thank you enough for this service. Tria Health is like a second set of eyes on my health. Appreciate the service. - Rhonda T. This patient was struggling to control their blood pressure... Read More There were multiple factors impacting this patient's blood sugar... Read More This patient’s HbA1c had jumped to 12%, which is... Read More Prior to taking a blood thinner, this patient was on... Read More Our pharmacist discovered that this patient’s treatment... Read More Improving your health can not only impact you, but your loved ones. Read More "I look forward to the call with the pharmacist..." Read More Our tobacco cessation program has a huge impact. Read More "This service has been life changing and a critical part of my..." Read More Every patient is unique and each condition requires customized care. Read More Tria Health’s pharmacists will go above and beyond for our members. Read More